pCDCAR1 CS1 h(b2cζ), NK(CAR-NK-2-M329-CZ)
The vector of anti-CS1 chimeric antigen receptor(CAR) is constructed for the engineering of NK cells to target Human CS1. The NK cells are genetically modified through transduction with a Lentiviral vector expressing scFv of anti-CS1 antibody linked to b2c and CD3-zeta signaling domains. And the vector product was designed for the treatment of multiple myeloma (MM).
Details
Targeting Cell Type
NK cell
Targeting Diseases
Multiple myeloma (MM)
Receptor Construction
scFv-b2c-CD3ζ
Discription of Signaling Cassetes
b2c
The b2c protein belongs to high-sulphur keratin family which comprises at least three proteins, B2A, B2B and B2C. And b2c in chimeric antigen receptors improve T-cell effector functions and enhance anti-tumor activity.
CD3ζ
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta,which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
Target
Gene Name
chorionic somatomammotropin hormone 1
Synonyms
PL; CSA; CS-1; CSMT; hCS-1; hCS-A; CD28; Chimeric antigen receptor; T cell; Retrovirus; CARs; Lentivirus; chimeric T cell receptors; chimeric immunoreceptors; chimeric antigen receptors; scFv; 162.1
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Related Products
| Cat# |
Description |
| CAR-T-2-L349-BZ |
Anti-CSH1 scFv h(41BB-CD3ζ) CART, pCDCAR1 |
| VP-CAR-LC162 |
Lenti-CSH1 CAR (scFv-CD4-FcεRIγ, 162.1) Viral Particle |
| CAR-NK-1-M329-G |
Anti-CS1 scFv h(FcεRIγ) CARNK, pCDCAR1 |
| VP-CAR-LC158 |
Lenti-CSH1 CAR (scFv-FcεRIγ, 162.1) Viral Particle |
| VP-CAR-LC168 |
Lenti-CSH1 CAR (scFv-CD28-OX40-CD3ζ, 162.1) Viral Particle |
| VP-CAR-LC165 |
Lenti-CSH1 CAR (scFv-41BB-CD3ζ, 162.1) Viral Particle |
| VP-CAR-LC161 |
Lenti-CSH1 CAR (scFv-CD28-CD3ζ, 162.1) Viral Particle |
| VP-CAR-LC160 |
Lenti-CSH1 CAR (scFv-CD28-FcεRIγ, 162.1) Viral Particle |
| CAR-NK-2-M329-BG |
Anti-CS1 scFv h(CD28-FcεRIγ) CARNK, pCDCAR1 |
| VP-CAR-LC167 |
Lenti-CSH1 CAR (scFv-CD28-41BB-CD3ζ, 162.1) Viral Particle |
Carcinoma
Kits for CARs/TCRs Development 
Datasheet
Subscribe to Our Newsletter for Updates: